IL13RA2 and glioblastoma: To overcome the inherent heterogeneity in GBM, there has also been work studying the use of a trivalent CAR T cell that targets IL13Rα2, EphA2, and HER2 that has demonstrated increased and sustained response in patient-derived xenografts (Bielamowicz et al., 2016).